CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 133 enrolled
Drug / intervention
Peginterferon alfa-2b (PEG) +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00863109
NCT00863109N/ACompleted
CompareCT.gov

Evaluation of the Health-Related Quality of Life During Combined Treatment of Chronic Hepatitis Due to Hepatitis C Virus Under Habitual Clinical Practise Conditions.

Merck Sharp & Dohme LLC·observational·Posted Mar 17, 2009·Updated Apr 7, 2017

In Brief

An observational study evaluating Peginterferon alfa-2b (PEG) and Ribavirin (RBV) for Hepatitis C, Chronic and 2 related conditions. Completed, enrolled 133 participants.

Detailed Summary

The primary objective of this study is to evaluate the impact of chronic hepatitis C (CHC), and the treatment thereof with peginterferon alpha-2b (PEG) and ribavirin (RBV) according to standard clinical practice, on the health-related quality of life (HRQL) of a cohort of participants throughout 72 weeks of follow-up. HRQL was assessed using the 36-Item Short-Form Health Survey (SF-36) and the Chronic Liver Disease Questionnaire-Hepatitis C Virus (CLDQ-HCV).

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsHepatitis C, Chronic, Genotype 1, HCV-1
Countries--
Collaborators--

Timeline

N/ACompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedMar 17, 2009
Enrollment StartApr 1, 2009
Primary CompletionMay 1, 2013
TodayJul 2, 2026
Enrollment to primary: 4.1 yearsPosted 17.3 years ago

Interventions

Peginterferon alfa-2b (PEG)biological

Pegylated interferon alfa-2b was administered in accordance with the dosage and pattern prescribed by each participant's physician (standard clinical practice).

Ribavirin (RBV)drug

Ribavirin was administered in accordance with the dosage and pattern prescribed by each participant's physician (standard clinical practice).